Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Bellus Health Inc (BLU) NPV

Sell:4.80 CAD Buy:5.10 CAD Change: 0.08 CAD (1.64%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:4.80 CAD
Buy:5.10 CAD
Change: 0.08 CAD (1.64%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Sell:4.80 CAD
Buy:5.10 CAD
Change: 0.08 CAD (1.64%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.

Contact details

Address:
275 Armand-Frappier Blvd
LAVAL
H7V 4A7
Canada
Telephone:
+1 (450) 6804500
Website:
www.bellushealth.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BLU
ISIN:
CA07987C2040
Market cap:
380.81 million CAD
Shares in issue:
78.34 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Francesco Bellini
    Chairman of the Board
  • Roberto Bellini
    President, Chief Executive Officer, Director
  • Ramzi Benamar
    Chief Financial Officer
  • Denis Garceau
    Senior Vice President - Drug Development
  • Francois Desjardins
    Vice President - Finance
  • Tony Matzouranis
    Vice President - Business Development
  • Catherine Bonuccelli
    Chief Medical Officer
  • Sebastien Roy
    Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.